Article Abstract

Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study

Authors: Gaelle Jeannin, Patrick Merle, Henri Janicot, Lise Thibonnier, Fabrice Kwiatkowski, Adel Naame, J. Baptiste Chadeyras, Géraud Galvaing, Aurélie Belliere, Marc Filaire, Pierre Verrelle

Abstract

Background: A retrospective monocentric study of consecutive patients with superior sulcus tumor nonsmall cell lung cancer (SS-NSCLC), treated by induction concurrent chemoradiotherapy (CRT), article management.
Methods: From 1994 to 2005, 36 patients (15 T3, 21 T4 tumors, including N2-N3 node involvement) received induction CRT with cisplatine/vinorelbine/fluorouracil combined with 44 Gy radiotherapy (5 daily 2 Gy fractions/week). After CRT completion, RECIST evaluation and operability were assessed. In resectable patients, surgery was performed one month after CRT. Patients with unresectable disease followed CRT up to 66 Gy. The median of follow-up period was 38.6 months [2-206].
Results: Induction CRT was completed for 94.4% with 71% radiological objective response (OR). Sixteen patients (44%) underwent surgical resection, and pathologic complete resection was performed in 93.8%. There were 7 patients (44%) with pathologic complete response. The median disease-free survival (DFS) time was 12.9 months with DFS rates at 1 and 2 years 53.6% and 39.1% respectively. The median overall survival (OS) was 46.4 months. The OS rates at 2 and 5 years were 68.8% and 37.5% respectively with no difference between T3 and T4 tumors. In unresectable disease, the median DFS time was 8.1 months. The DFS rate at 1 year was 25.2%. The median OS was 9.1 months. The OS rates at 1 and 2 years were 45% and 16.9% respectively. Recurrences were found in 72% of patients. Brain metastasis was the most common site of recurrence. Prognostic factors for OS were the response to induction treatment, the possibility of surgery, and pathologic complete response.
Conclusions: This trimodality treatment regimen confers a survival outcome in agreement with previous studies. Patients with pretreatment N3 lymph node should be included in trimodality treatment.

Refbacks

  • There are currently no refbacks.